CLINICAL CASE OF MULTIMODALITY TREATMENT OF METASTATIC BLADDER CANCER
https://doi.org/10.21294/1814-4861-2019-18-6-140-144
Abstract
Background. Bladder cancer is one of the most common cancers. Non-muscle-invasive bladder cancer is characterized by the high frequency of recurrence after radical treatment (up to 50–60 %), and muscle-invasive bladder cancer has a lower recurrence rate (30 %). Primary metastatic bladder cancer (Bc) is detected in 10–15 % of cases. transurethral resection of the bladder is the main treatment modality for non-muscleinvasive Bc. For muscle-invasive Bc, radical cystectomy is the curative treatment of choice. chemotherapy is used for the treatment of metastatic Bc. the role of surgery for metastatic Bc has not yet been determined. there are only a few reports regarding multimodality treatment including metastasectomy for metastatic Bc. Case description. We present a clinical case of successful treatment of metastatic Bc, we used surgery, radiotherapy, chemotherapy and x-ray endovascular technologies. the patient is alive with no evidence of disease. Conclusion. Our findings are consistent with other reports which indicate that the removal of metastases in patients with advanced urothelial carcinoma is technically feasible and can be safely performed. Metastasectomy can have a positive effect on survival. However, metastasectomy remains the subject of clinical studies, and should be recommended only for patients a good response to systemic therapy.
About the Authors
A. V. Lykov
Tyumen State Medical University of the Ministry of Healthcare of Russia,
Joint-stock company Medical unit «Neftyanik»
Russian Federation
Russian Federation
MD, PhD, Assistant Professor of Oncology with a course of urology; Head of the Regional Urological Center
54, Odesskaya st., tyumen-625023, Russia
12, schiller st., tyumen-625048, Russia
V. G. Znobishchev
Joint-stock company Medical unit «Neftyanik»
Russian Federation
Russian Federation
MD, Physician
12, schiller st., tyumen-625048, Russia
I. B. Popov
Joint-stock company Medical unit «Neftyanik»
Russian Federation
MD, PhD, Director
Russian Federation
MD, PhD, Director
12, schiller st., tyumen-625048, Russia
A. A. Keln
Tyumen State Medical University of the Ministry of Healthcare of Russia,
Joint-stock company Medical unit «Neftyanik»
Russian Federation
Russian Federation
MD, Assistant of Oncology with a course of urology; Physician of Oncourology Department
54, Odesskaya st., tyumen-625023, Russia
12, schiller st., tyumen-625048, Russia
References
1. Bladder cancer. Clinical recommendations. 2018. [Internet]. URL: https://oncology-association.ru/files/clinical-guidelines_adults%C2%A0-%20projects2018/rak-mochevogopuzyrya_pr2018.pdf (cited 5.02.2019). (in Russian).
2. Lykov A.V., Keln A.A., Zyryanov A.V., Ponomaryov A.V. Problems of surgical complications of radical cystectomy: experience one clinic. Ural medical journal. 2017; (2): 109–113. (in Russian).
3. Kel’n A.A. Analysis of the results of radical treatment of patients with muscle-invasive bladder cancer. Universitetskaya meditsina Urala. 2016; 2(5): 27–29. (in Russian).
4. Rosenberg J.E., Carroll P.R., Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1): 14–20. doi: 10.1097/01.ju.0000162039.38023.5f.
5. Muscle-invasive and Metastatic Bladder Cancer» EAU Guidelines, 2018 [Internet]. URL: https://uroweb.org/guideline/bladder-cancer-muscleinvasive-and-metastatic (cited 5.02.2019).
6. von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20; 23(21): 4602–8. doi: 10.1200/JCO.2005.07.757.
7. Bellmunt J., Théodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., Caty A., Carles J., Jagiello-Gruszfeld A., Karyakin O., Delgado F.M., Hurteloup P., Winquist E., Morsli N., Salhi Y., Culine S., von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20; 27(27): 4454–61. doi: 10.1200/JCO.2008.20.5534.
8. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., Shen X., Boyd Z., Hegde P.S., Chen D.S., Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27; 515(7528): 558–62. doi: 10.1038/nature13904.
9. Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A., Dawson N., O’Donnell P.H., Balmanoukian A., Loriot Y., Srinivas S., Retz M.M., Grivas P., Joseph R.W., Galsky M.D., Fleming M.T., Petrylak D.P., Perez-Gracia J.L., Burris H.A., Castellano D., Canil C., Bellmunt J., Bajorin D., Nickles D., Bourgon R., Frampton G.M., Cui N., Mariathasan S., Abidoye O., Fine G.D., Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7; 387(10031): 1909–20. doi: 10.1016/S0140-6736(16)00561-4.
10. Bellmunt J., de Wit R., Vaughn D.J., Fradet Y., Lee J.L., Fong L., Vogelzang N.J., Climent M.A., Petrylak D.P., Choueiri T.K., Necchi A., Gerritsen W., Gurney H., Quinn D.I., Culine S., Sternberg C.N., Mai Y., Poehlein C.H., Perini R.F., Bajorin D.F.; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Mar 16; 376(11): 1015–1026. doi: 10.1056/NEJMoa1613683.
11. Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J., Plimack E.R., Vaena D., Grimm M.O., Bracarda S., Arranz J.Á., Pal S., Ohyama C., Saci A., Qu X., Lambert A., Krishnan S., Azrilevich A., Galsky M.D. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar; 18(3): 312–322. doi: 10.1016/S1470-2045(17)30065-7.
12. Iwamoto H., Izumi K., Shimura Y., Natsagdorj A., Maolake A., Takezawa Y., Nohara T., Shigehara K., Kadono Y., Mizokami A. Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res. 2016 Oct; 36(10): 5557–5561. doi: 10.21873/anticanres.11140.
13. Abe T., Matsumoto R., Shinohara N. Role of surgical consolidation in metastatic urothelial carcinoma. Curr Opin Urol. 2016 Nov; 26(6): 573–80. doi: 10.1097/MOU.0000000000000329.
14. Matsuguma H., Yoshino I., Ito H., Goya T., Matsui Y., Nakajima J., Ikeda N., Okumura S., Shiono S., Nomori H.; Metastatic Lung Tumor Study Group of Japan. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? Ann Thorac Surg. 2011 Aug; 92(2): 449–53. doi: 10.1016/j.athoracsur.2011.03.097.
15. Patel V., Collazo Lorduy A., Stern A., Fahmy O., Pinotti R., Galsky M.D., Gakis G. Survival after metastasectomy for metastatic urothelial carcinoma: a systematic review and meta-analysis. Bladder Cancer. 2017 Apr 27; 3(2): 121–132. doi: 10.3233/BLC-170108.
16. Abufaraj M., Dalbagni G., Daneshmand S., Horenblas S., Kamat A.M., Kanzaki R., Zlotta A.R., Shariat S.F. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol. 2018 Apr; 73(4): 543–557. doi: 10.1016/j.eururo.2017.09.030.
17. Cowles R.S., Johnson D.E., McMurtrey M.J. Long-term results following thoracotomy for metastatic bladder cancer. Urology. 1982 Oct; 20(4): 390–2.
18. Siefker-Radtke A.O., Walsh G.L., Pisters L.L., Shen Y., Swanson D.A., Logothetis C.J., Millikan R.E. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004; 171: 145–148. doi: 10.1097/01.ju.0000099823.60465.e6.
19. Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J.E., Fechner G., Spahn M., Heidenreich A., Odenthal A., Seif C., Nürnberg N., Wülfing C., Greb C., Kälble T., Grimm M.O., Fieseler C.F., Krege S., Retz M., Schulte-Baukloh H., Gerber M., Hack M., Kamradt J., Stöckle M. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol. 2009 Jun; 55(6): 1293–9. doi: 10.1016/j.eururo.2008.11.039.
20. Nakagawa T., Taguchi S., Kanatani A., Kawai T., Ikeda M., Urakami S., Matsumoto A., Komemushi Y., Miyakawa J., Yamada D., Suzuki M., Enomoto Y., Nishimatsu H., Kondo Y., Nagase Y., Hirano Y., Okaneya T., Tanaka Y., Miyazaki H., Fujimura T., Fukuhara H., Kume H., Igawa Y., Homma Y. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate? Ann Surg Oncol. 2017 Sep; 24(9): 2794–2800.
Review
For citations:
Lykov A.V., Znobishchev V.G., Popov I.B., Keln A.A. CLINICAL CASE OF MULTIMODALITY TREATMENT OF METASTATIC BLADDER CANCER. Siberian journal of oncology. 2019;18(6):140-144. (In Russ.) https://doi.org/10.21294/1814-4861-2019-18-6-140-144
Views:
1055
Email this article 
